Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GEMOX chemo holiday plus regorafenib in high-risk post-surgical cholangiocarcinoma
ChiCTR2200060111Phase 4Not yet recruiting
- Sponsor
- Sir Run-Run Shaw Hospital
- Start
- Jun 2022
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of gemcitabine, oxaliplatin and regorafenib in cholangiocarcinoma (CCA) and biliary cancer (2 cohorts), sponsored by Sir Run-Run Shaw Hospital. Primary endpoint: Chemotherapy completion. Planned start Jun 2022; status: not yet recruiting.
02
Drugs
gemcitabineoxaliplatinregorafenib
03
Conditions
cholangiocarcinoma (CCA)biliary cancer
Beyond the preview
Go deeper on ChiCTR2200060111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200060111.